Pii Invests in Expansion of Sterile Fill-Finish Capacity & Capabilities
Pii has strategically invested in expansion of our sterile fill-finish capacity and capabilities, with production lines capable of supporting large commercial scale batch sizes. Specifically, Pii has increased their investment in the Bosch Aseptic Filling Line, increasing the ability to perform Large Volume Sterile Fill-Finish production needed for manufacturing most vaccinations.
“Throughout the past year, we have seen many vaccinations to tackle the COVID-19 pandemic. With the CDC now recommending booster shots to Americans, we are presented with a vaccine manufacturing capacity challenge,” said Kurt Nielsen, President & CEO of Pii. “Not only does our industry have to manufacture the COVID-19 Vaccines (including the booster shot), but we have to continue manufacturing the everyday vaccines including the annual Flu vaccine, Pneumovax23, Twinrix, and many more.”
Pii’s Increased Biologic/Vaccine Fill & Finish Capabilities Include:
- Batch Sizes from 1 L-1000 L
- Vials (2 mL-100 mL) – Bosch® FWR 4080
- Clean rooms ranging from class 100 to 100,000
- Glass, COC & COP vials & syringes
- Ability to support disposable, single-use technology with varying mixing and temperature conditions
- Refrigerated Storage
Pharmaceutics International, Inc. (Pii) is a US-based contract development and manufacturing organization (CDMO) with a passion for solving problems. Pii’s Hunt Valley, Maryland campus includes 70 manufacturing suites with four integrated aseptic filling lines delivering quality, safety, and efficiency. Our professionals have extensive experience with small and large molecule compounds, developing and manufacturing complex parenteral drugs, extended-release formulations, non-aqueous injectable drug products, and lyophilization. For more information, visit www.pharm-int.com. Learn about Pii’s Vaccination Capabilities at: www.pharm-int.com/vaccine-tech-transfer.
Total Page Views: 983
